Axogen Reports Strong Preliminary Q4 and Full-Year 2025 Revenue Growth, Driven by Avance® BLA Approval

summarizeSummary

Axogen announced strong preliminary unaudited Q4 and full-year 2025 financial results, with revenue growth exceeding 20% year-over-year, supported by solid gross margins and an improved cash position, and highlighted the impact of the recent Avance® BLA approval.

check_boxKey Events

• Preliminary Q4 2025 Revenue

  Fourth quarter 2025 revenue is expected to be approximately $59.9 million, representing a 21.3% increase over Q4 2024.

• Preliminary Full-Year 2025 Revenue

  Full-year 2025 revenue is expected to be approximately $225.2 million, a 20.2% increase over full-year 2024.

• Strong Gross Margin

  Gross margin for both Q4 and full-year 2025 is expected to be above 74%, despite one-time costs related to the Avance® BLA approval.

• Improved Cash Position

  Cash, cash equivalents, restricted cash, and investments are expected to be approximately $45.5 million as of December 31, 2025, an increase of $6.0 million from the end of 2024.

auto_awesomeAnalysis

Axogen's preliminary financial results for Q4 and full-year 2025 demonstrate robust revenue growth and improved financial health. The significant year-over-year revenue increases, coupled with strong gross margins and an improved cash position, indicate effective execution of the company's commercial strategy. The recent FDA Biologics License Application (BLA) approval for Avance® is a critical milestone, providing a strong foundation for future growth and reinforcing investor confidence, especially as the stock trades near its 52-week high. These results suggest positive momentum for Axogen's market development and product portfolio.